Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigational drug · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Investigational drug | DRUG | - |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: Eligible patients must be at least 18 years of age with a diagnosis of NSCLC that has gotten worse during or after treatment with plati...
The investigational drug is being studied for use in oncology, specifically in carcinoma, non-small-cell lung cancer and multiple myeloma. Clinical trials have evaluated it in adult patients with non-small-cell lung cancer and in adult patients with multiple myeloma.
The investigational drug is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research on this small molecule oncology candidate.
The investigational drug has completed a Phase 2 clinical trial in non-small-cell lung cancer and a Phase 1 clinical trial in multiple myeloma. It remains an investigational drug in clinical development and is not approved by regulatory authorities.
The investigational drug has been studied in two completed clinical trials. NCT00034957 was a Phase 2 study in adult patients with non-small-cell lung cancer, and NCT00036140 was a Phase 1 study in adult patients with multiple myeloma. Both trials were conducted in the United States.
Yes, the investigational drug is a small molecule therapeutic. It is being developed as an oncology treatment and has been evaluated in clinical trials for non-small-cell lung cancer and multiple myeloma.